Floatz logo

FLUDROCORTISONE

Prostate Cancer (Adenocarcinoma)

Acerand Therapeutics (Hong Kong) LimitedSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

17 Active assets in the Prostate Cancer (Adenocarcinoma) cohort.

Asset / SponsorPhaseRating
Darolutamide
Region Stockholm
Phase 3BB
25-HYDROXYCALCIFEROL
University of Ilorin Teaching Hospital
Phase 3B
METRONIDAZOLE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
Sacituzumab Tirumotecan
Tianjin Medical University Second Hospital
Phase 2CCC
Valaciclovir
Candel Therapeutics, Inc.
Phase 2CCC

View all 17 →

Same molecule, other indications

FLUDROCORTISONE is also rated in:

Advanced Metastatic Castration Resistant Prostate CancerDormant
BB
Indicative ·
70 / 100
View asset →
congenital adrenal hyperplasiaDormant
BB
Indicative ·
69 / 100
View asset →
Parkinson diseaseDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →